HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Interactions between histone deacetylase inhibitors (HDACIs) and decitabine were investigated in models of diffuse large B-cell lymphoma (DLBCL). A number of cell lines representing both germinal center B-like and activated B-cell like DLBCL, patient-derived tumor cells and a murine xenograft model...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kalac, Matko, Scotto, Luigi, Marchi, Enrica, Amengual, Jennifer, Seshan, Venkatraman E., Bhagat, Govind, Ulahannan, Netha, Leshchenko, Violetta V., Temkin, Alexis M., Parekh, Samir, Tycko, Benjamin, O'Connor, Owen A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217353/
https://ncbi.nlm.nih.gov/pubmed/21772049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-336891
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak